๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC ยท Real-Time Price ยท USD
0.3699
-0.0139 (-3.62%)
At close: Nov 18, 2026, 4:00 PM EST
0.3504
-0.0195 (-5.27%)
Pre-market: Nov 19, 2026, 7:58 AM EST
โ† View all transcripts

UBS Global Biopharma Conference 2026

Nov 17, 2026

Summary

A $77 million PIPE is funding a planned 2027 Phase II trial of psilocybin-based therapy for CRPS, with interim data expected in H2 2027. An 11-molecule ergoline pipeline is advancing toward first patient dosing in Q1 2028.

Speaker 1

Right.

Richard Langford
CMO, Cy Biopharma

Come so many years.

Speaker 1

Good day, everybody. Welcome back to UBS Global Biopharma conference in London. Our next session, Ensysce Biosciences, very, very excited to learn about the story. We have the whole team, so thank you so much for joining, and my name is Ash from UBS with Cap Biotech and Spec Pharma. But would love to hear the story out, James, Richard, Roger, and Paul. I know we have some slides to go through, and then we can get into some Q&A after that.

James Morrison
President, Ensysce Biosciences

Perfect.

Richard Langford
CMO, Cy Biopharma

Yeah.

James Morrison
President, Ensysce Biosciences

Thank you for having us.

Richard Langford
CMO, Cy Biopharma

Have we got the-

Speaker 1

Yeah

Richard Langford
CMO, Cy Biopharma

need the clicker.

James Morrison
President, Ensysce Biosciences

If we're sitting here.

Richard Langford
CMO, Cy Biopharma

There we go.

James Morrison
President, Ensysce Biosciences

Oh, this is coming off. We're now scrolling through the-

Speaker 1

I see.

Richard Langford
CMO, Cy Biopharma

Could we have our first slide, please?

James Morrison
President, Ensysce Biosciences

Oh, it's actually coming. It's not showing down here.

Richard Langford
CMO, Cy Biopharma

Oh, it's not showing.

James Morrison
President, Ensysce Biosciences

but it is showing up there.

Richard Langford
CMO, Cy Biopharma

In that case, I will go to the lectern to start things off.

Speaker 1

Yep.

Richard Langford
CMO, Cy Biopharma

So we can actually see. No, that is not our-

James Morrison
President, Ensysce Biosciences

There it is.

Richard Langford
CMO, Cy Biopharma

There we go. Fine. So, thank you very much. We are going to be talking about our neuroplastogenic therapies, and we will explain about psychedelics and bringing resilience and motivation to our, hopefully in the future, to many patients suffering from severe chronic pain. To set the scene for you, I am going to pass over initially to Roger to tell you about the business and commercial side of things.

Roger Sawhney
CFO and CBO, Cy Biopharma

Terrific. Thank you, Richard. Very quickly, we are a new company, in the sense that we just did a reverse merger, actually with Ensysce Biosciences. This is Cy Biopharma, and as Richard said, we are focused on the psychedelics space and using psychedelics for neuropathic pain syndromes. The transaction, the reverse merger was closed in August of this year. We were fortunate to raise a $77 million PIPE alongside that with some leading investors, including Perceptive, Ally Bridge Group, Dellora Investments, Ikarian Capital, and Adage. So we are excited about our investors and new investors coming aboard as well. We will be using that cash, obviously, to conduct clinical trials for our lead project in CRPS, as well as to drive novel therapeutics, novel ergolines for additional indications. We will talk about all of that in discussion today.

Richard Langford
CMO, Cy Biopharma

I am going to describe a little about our indication that we are going to be trialing our lead asset in, and tell you a little of the story of how we got to where we are, and then be handing over to colleagues to take you through some of our future plans as well. To begin with, complex regional pain syndrome is a relentless, severely painful condition. Regional because it affects usually the distal part of a limb. It is not in the precise distribution of a nerve, but it is in the region of the hand and wrist or foot and ankle, commonly, but not always, with a history of injury, either minor or major, or surgery.

When all of the healing is done and everything anatomically looks fine, the patient is still left with severe, relentless, persistent pain and exquisite tenderness in the hand and wrist or the foot and ankle. It becomes swollen and stiff. There can be other changes as well in the autonomic nervous system, and we know there are major changes in the central nervous system, as there are in many chronic pain conditions, but even more so in complex regional pain syndrome than perhaps more overtly than in some other pain conditions. There are also significant changes in the way that pain is modulated in the spinal cord and in the brain and the way that pain is perceived. Inextricably linked with chronic pain, we know, are mental health maladaptations.

In addition to things like catastrophization, anxiety, and depression, one also sees in this group of patients, for example, a neuropsychiatric condition in which many of them see the limb as misshapen and swollen. They come to loathe the limb and can even, in extreme circumstances, request amputation. It is a horrible condition. It affects 200,000 people at any one time in the U.S., for example, with that condition diagnosed. We were granted a U.S. FDA orphan designation for our treatment in CRPS in January of this year.

We believe, and we have some preliminary data that I am going to show you very shortly, which shows that we believe that the neural reset, which is spoken so much of in the psychiatric setting these days with psychedelic therapy, that that can be of benefit to patients with long-term pain conditions, particularly CRPS, which we believe could be our springboard to other indications as well. CY200 is a botanical formulation and is predominantly psilocybin, and it is an oral formulation, will be administered in a medically supervised setting, a little bit like a procedure, if you like. As I will show you, we believe that that intervention could lead to durable benefit. There is some history to the use of psychedelics in pain. LSD in the 1960s and 1970s. I am not going to take you through any of the detail, and you cannot read it, obviously.

There is too much there. But there is a history, anecdotal case reports, academic reports of LSD having benefit, and more recently in the last 20 years, reports and little case series of psilocybin having benefit in pain conditions. As you know, psilocin is the active moiety. Psilocybin, if you like, the prodrug, and psilocin can produce the neural reset, which, as we know, is well-described in psychiatry and neuroscience. It also has anti-neuroinflammatory benefit, which is significant in the chronic pain area. There is also some animal data, which I am not going to take you through, but there is plausible animal data to show the benefits of psilocybin in long-term pain conditions. This is the briefest glimpse, and obviously, again, there is too much data to read all of it or go through all of it.

But the message here is, each row in that table is a single individual. The top two are actually case reports from the U.S. in 2023 and 2024, with multiple doses of, in one case, mushrooms, in the second case, psilocybin, showing reduction in pain in intractable cases of CRPS with pain, despite other treatments that could not be reduced to a low enough level. In Oregon, where there is health legislation permitting the dosing of individuals with psilocybin, of course, we provided a grant. This was an investigator-initiated study, if you like, conducted by one of the dosing centers in Oregon in six individuals, in four in 2025 and two this year, in January of this year, who received psilocybin, botanical psilocybin, about 25 mg, single dosing.

The messages from the data that was collected there in that open-label observational study was that there were pain reductions in all of the individuals. In half of them, it was above the threshold for being clinically meaningful, and of accepted benefit by the regulators and pain science and so on. Also a whole raft of benefits in activities of daily functioning, mood, sleep, general well-being, and so on. Of course, that was open label, but of interest for that, and even equally of interest for our ongoing studies, or studies we are going to be conducting probably starting in 2027, is that there is a very low placebo rate in CRPS, unlike some other pain and mental health conditions. So that is of use when you are considering the data I have just shown you and the data that will be coming in future years.

The phase II study that we have submitted to the MHRA and are in the process of just interaction with the MHRA in the U.K., and having received a positive ethics response as well, will run in 2027, probably in both the U.S. and in U.K. I am not going to go into great detail, but it is essentially 0, 10, and 25 mg of psilocybin that will be given to people with CRPS with moderate to severe pain between five and nine on the 0 - 10 scale. One group will have two doses of 25, so that we can see, first of all, we hope to show separation of the first dose from placebo, especially in the 25 mg dosage, and then whether twice 25 is better than 25 once.

That will be three weeks apart, just like the Compass Pathways study that has already been reported, showing a high responder rate. We will follow them out for three months. I am not going to dwell on this, but just to say that it has been modeled in commercial terms and is shown to be a valuable proposition from a market point of view in terms of patient numbers out there. This is actually underpriced compared with what is now being spoken of as the sort of pricing for this treatment. So, with that, I am going to hand over to my colleague, Paul Wren, who is a CSO in Cy Biopharma, to tell you a little bit about the future.

Paul Wren
CSO, Cy Biopharma

Yeah. Thank you very much, Richard. I think the exciting thing is, if you take the playbook from interventional psychiatry, maybe dial back seven to 10 years, we are now at that point in pain where actually we are going to try to run the first ever randomized control clinical trial to get bona fide qualified data from all that anecdotal data. So, as Richard says, the psilocybin is a great opportunity to create a beachhead in CRPS. But behind the scenes, we actually have a novel class of molecules, so actual novel chemical entities that are based around LSD, a full freedom to operate. These molecules are actually from two patent families that have already been published. They are just entering into national phase, 15 countries.

The reason why these are potentially even more exciting than the tryptamines, if you come from a molecular pharmacology background, I get very excited because ergolines, the class, actually have a broader depth of pharmacology. This could be extraordinarily important for durability of effect, efficacy size, but also capturing multiple of those comorbid states. One area where ergolines have a significant differentiation compared to the tryptamines is bringing in dopaminergic pharmacology. Not only will that add in reducing nociceptive transmission, it will actually help to shape the plasticity. In other words, to go from rigidity of a maladaptive state to enable it to become flexible, to overcome that maladaptive state and tap into motivational aversive states, as well as, very importantly, in motor control to facilitate rehabilitation that ultimately enables a collective resilience to a chronic pain state.

As Richard alluded to, there are multiple different data sets, and this is actually a new emergent field. You won't see much, even in the preclinical literature. What's extraordinarily fascinating, there are a cluster of studies done with psilocybin in animal models. Essentially, when you have a chronic persisting pain, psilocybin is very active for a long period. If you only look at a short, acute, and accumulating pain, it's not as active. This is very consistent with a psychedelic works best when you're in a most persistent maladaptive state. At the same time, there have been recent studies with LSD in a similar fashion, where essentially you drive a persistency in the pain, and again, you see an acute response that is extraordinarily durable from a single dose.

Both these studies are showing that in the actual architecture of the brain, the hyperexcitability, so neurons are firing very fast, in the anterior cingulate cortex is actually dampened, consistent with that reversal of the chronic pain state. Why is this important? This is extraordinarily important because it's actually the linkage between interventional psychiatry and chronic pain, because they are managed by the top-down control through the cortical networks. We already have clues as to actually how these drugs work, and now we need to accelerate them into the clinic to be able to demonstrate their long-term durability. So where are we? These are new molecules. We actually are very excited that we have a cluster of 11 lead molecules.

These are going through what I call a triaging exercise, which brings different facets of absorption, distribution, metabolism, excretion, and pharmacology to help us to ultimately select which is going to be our candidate molecule, as well as a backup. This data we should have in hand in three months' time, so we're already having a bet across the chairs as to which one's the winner, chicken dinner. More importantly, we've already engaged the pipeline to swiftly move into IND-enabling studies, as well as actually manufacturing drug product for clinical trials. Our goal is actually, with these novel ergolines, to start dosing patients in Q1 2028.

James Morrison
President, Ensysce Biosciences

This is our anticipated development plan, which is, I think it is worth pointing out, that although CRPS is a relatively rare condition, it is not ultra-rare. It is not an extremely difficult condition to recruit in. If you couple that with the fact that this class of molecule is particularly well talked about in the public, we are anticipating to be able to recruit for these studies fairly quickly. The aim is to be through the phase II within the next year or so, and then moving into a pivotal trial with a kind of target submission date in around the beginning of 2030.

Speaker 1

Great. Yeah. Thank you so much for that. I think this slide sort of gave a foundation for the content, and so thanks for providing that background. Maybe I will just start by asking that, I mean, there is a lot of focus and attention on psychedelics, particularly in the last few years. But a lot of those companies have been going after very well-established disease states, psychiatry, TRD, PTSD, right? Like, common GAD. But I guess your approach is very orthogonal in the sense that you are going after a pain market, which is very big, and provides some sort of significant potential. What drove that thinking, like when you started to look at the application of psilocybin to pain in general, and how did you land on CRPS to begin with?

Paul Wren
CSO, Cy Biopharma

Well, there is actually a fair amount of case studies, reports out there. If you look at the patients, there are patients asking, "Where can I get

psilocybin mushrooms. There is something we read online, and this goes to what we have seen later on in the studies that we see in Oregon, which says, "My husband couldn't walk. He took psilocybin mushrooms. He had CRPS, and then he could rehabilitate. He could walk. Where can I get psilocybin mushrooms from?" Then there are studies at Johns Hopkins, kind of small case reports, an army lawyer who had a pain level of nine, kind of on suicidal levels of pain, and multiple doses of psilocybin brought that down to 0. You can see her testimony in the FDA public hearing.

Speaker 1

Yeah.

James Morrison
President, Ensysce Biosciences

There is also, from my side, a personal experience. I spent some time in Great Ormond Street Hospital as a teenager, dealt with chronic pain, and found psychedelics to be a more effective form of pain relief and general resilience building than whatever is currently available out there. I really feel that this needs to be brought to patients as quickly as possible.

Speaker 1

Is there any uniqueness about the CRPS setting versus the overall pain? Pain can be a big market with a lot of different segmentation. When you think about, let's say, if this application towards CRPS is successful, does that open other pain opportunities for you?

James Morrison
President, Ensysce Biosciences

Well, you could actually speak to the uniqueness of CRPS and the kind of-

Richard Langford
CMO, Cy Biopharma

Yeah.

James Morrison
President, Ensysce Biosciences

Yeah.

Richard Langford
CMO, Cy Biopharma

CRPS we see as a good opportunity as a springboard to other indications in the pain area, and possibly outside the pain area. But for now, within the pain area is on our radar. CRPS, we believe, is a good option to start with, aside from the obvious advantage that we have gained the orphan designation and with it being a relatively rare condition. Because of the significant nature of the pain that is, as I say, relentless, generally severe, the average pain score coming into a pain study with CRPS is around seven to eight. That is at least one or two points higher than, say, many arthritis studies or back pain studies would be, for example.

The fact that these individuals find it so difficult to rehabilitate, because they can't bear to have the limb touched, it can't be actively manipulated by a physical therapist, or they can't do the exercises themselves. We hope that the combination of reduction of pain and increasing their motivation and resilience with the neural reset will help them to rehabilitate as well. What I've described in CRPS is, to a greater or lesser extent, found in many chronic pain conditions, and there's an inextricable bidirectional link between mental health and chronic pain. Indeed, many chronic pain patients, when they are carefully assessed, will report things like PTSD and abuse in childhood and so on. There can be a lot of mental health conditions leading to chronic pain, and equally, chronic pain leads to mental health decline.

All of that wraps together to suggest to us that psychedelic therapy, whether it be psilocybin or, in future, the ergoline, may well have a good place.

Paul Wren
CSO, Cy Biopharma

Maybe, Ash, if you think about, sorry, I'm a scientist, right? You can tell, circuitry. Pain is really driven by three pathways. You have an ascending pathway, which is classically where stimulus evokes activity. Then you have a central pathway which becomes super sensitized, so that as the stimulus is withdrawn, there's actually still a windup of perception of pain at the central level. Then you have a descending pathway, which is essentially a brake system. What happens in a pain condition is you get activation, your ascending pathway starts to fire, you get this sensitization, but as that sensitization increases in the brain, you take away the stimulus, it keeps winding. What fails in the chronic pain state is that the brake doesn't come into play. If the brake doesn't come into play, you just continue to drive a maladaptive central focus.

If you have a maladaptive central focus, and you think, "What is the core mechanism in interventional psychiatry of psychedelics?" It's actually at that central level, the central axis that's pivotal to connecting pathways in pain. But the advantage is that the molecular fingerprint of psychedelics can also dampen the neurogenic inflammation that's on the ascending pathway and can facilitate the brake. It's like a psychedelic is actually the best driver of any car, whether it's a classic shift or if it's, as I got used to when I went to the U.S., automatic or even a Waymo. Hopefully that helps.

Speaker 1

Yeah. No, that's super helpful. And maybe just briefly touch on what's the molecular entity. I know you have a few follow-on programs as well, just the difference between the CY200 and 201.

Paul Wren
CSO, Cy Biopharma

Yeah.

Speaker 1

Whoever wants to.

Richard Langford
CMO, Cy Biopharma

Yeah. CY200 is psilocybin predominant capsules. And of course, as I was saying, psilocybin is the prodrug, and that is rapidly converted to psilocin or psilocin in the body, and that is the active moiety. CY201 is a liquid formulation which is psilocin or psilocin predominant. So there is a differentiation between 200 and 201. We also have significant IP protection for CY201 as well, because of its mode of manufacture and the actual entities in the formulation.

Speaker 1

Got it.

Richard Langford
CMO, Cy Biopharma

Then the compounds beyond that are the ergolines that Paul was talking about, and we have this, as he was describing, this library of novel analogs, all with protection. In fact, I think they have just been launched in 15 countries

Paul Wren
CSO, Cy Biopharma

That is right. Yeah.

Richard Langford
CMO, Cy Biopharma

with the national IP protection in the last few days. They are currently undergoing, as we have heard, their sort of pre-IND work in the labs.

Paul Wren
CSO, Cy Biopharma

The nice thing about this is, because they are early molecules, you sort of have LSD as the parent family where it is fixed in stone what its pharmacology is. What we have in these 11 molecules is different levers that change the ratio of the pharmacology that enables us to explore the difference of what that differential pharmacology brings. What that means is that LSD will have its effect that is strong and that is persistent, but it may not have the absolute appropriate characteristics for different populations. What we anticipate with the ergolines is actually building a portfolio of diverse assets that can fit into different indications. For example, in some pain conditions where you might have a higher somnolent state versus others, other pain conditions where you might have a higher anxiety status.

These levers are extraordinarily malleable, enable us to build a further portfolio.

Speaker 1

Great. Perfect. Maybe if we talk about the study a little bit. The protocol that you have proposed, that is approved by the MHRA? Just in terms of the next steps to get the IND approval, just if you can talk a little bit about what would drive that. Really interested to understand that, you have a placebo arm. Most of the companies now got this understanding that they need a super-normal dose as a control. What drives your conviction that you can actually use placebo?

Richard Langford
CMO, Cy Biopharma

Yes. To clarify-

Speaker 1

Yeah

Richard Langford
CMO, Cy Biopharma

We submitted in the autumn to combined the IRAS application in the U.K. It goes simultaneously to the IRB and to MHRA. The IRB, essentially a few minor tweaks to the patient information sheet, and that is approved. The MHRA had, as we expected, especially with a novel botanical, a few questions which we are currently addressing. We will be responding to those, and the plan is that we will be looking to start the phase II that you see before you on the screen.

Speaker 1

Yeah.

Richard Langford
CMO, Cy Biopharma

The phase II in the first half of next year, and data emerging during the second half. The interim readout, when we've reached primary objective in half the patients, that'll be in 52 patients, and then, of course, the final readout towards the end of the year in the 104 patients. Four groups, 26 each, 0, 10, 25 mg once, and 25 mg twice. That's the structure of it. I was saying they have to come in, obviously, with an established diagnosis of CRPS and a pain score that's in the five to nine range. We'll then follow them with multiple outcomes that we look at. The primary objective, of course, based on pain. That is after the single dose, but with a key secondary with the second dose. We compare twice 25 with 25.

A raft of questionnaires, bit of a burden on the subjects, on the participants, but a raft of questionnaires to establish whether there are improvements in functioning, activity, daily life, the burden of their pain, if we've been able to relieve that. Plus reports of whether or not they've now been able to rehabilitate, whether they've been able to dispense with walking aids, and actual some objective data that we hope to collect from a wearable device that we've just selected with our CRO to show step data and other activity. That's the sort of program for next year with the phase II POC.

Speaker 1

Okay. But you feel confident that using placebo here, and then, yeah, if you can talk about the endpoint for CRPS, would the validated endpoint still be like a VAS score or anything?

Richard Langford
CMO, Cy Biopharma

It's the NRS score on the-

Speaker 1

NRS.

Richard Langford
CMO, Cy Biopharma

0 - 10 scale, showing it's a responder. The primary objective is based on the number of responders, and a response, as I was saying, is 30% or two-point reduction on the scale. That will deem you, classify you as a responder, and then it's based on the percentage of the participants who show a response.

Speaker 1

Okay.

Paul Wren
CSO, Cy Biopharma

Ash, just on the blinding aspect, that obviously if you take psychedelic, you know that you're on a psychedelic. There's a couple of things that's really nice about the design. From interventional psychiatry, 10 really doesn't drive subjective effects that are majorly noticeable. Having a lower dose acts as the sort of bridge from a placebo effect. That's one aspect built in. This was actually very successful in transitions from phases for Compass Pathways, for example. The second thing is, when you have a medicine that has the horsepower to be able to have an acute but a durable effect, what you actually see is the placebo may drop a certain percent, but your drug is going to drop a huge percent. The placebo comes back very quickly, but then you've got an absolutely sustained effect for weeks.

You actually, through the dose response and through the durability, mitigate the expectancy that might come from a psychedelic trial.

Richard Langford
CMO, Cy Biopharma

As we saw earlier, we know that in this particular condition, the placebo effect is extremely low anyway.

Speaker 1

Yeah. Great. Awesome. I mean, we are out of time. That was quick, but this was great. Thank you so much for going through the story. Looking forward to all the updates and exciting time to be in this space.

Richard Langford
CMO, Cy Biopharma

Thank you very much.

Speaker 1

Thanks, guys, for joining.